BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...

A groundbreaking collagen-based dermal filler has officially launched in the Philippines, promising a new approach to facial ...

PKU is a rare, inherited metabolic disorder that prevents the body from breaking down the amino acid phenylalanine. Untreated phenylketonuria can lead to brain damage, intellectual disabilities ...

SAN RAFAEL, CA, USA I April 2, 2025 I BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ ® (pegvaliase-pqpz) met its primary efficacy ...

San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.

Protein aggregation, denaturation, and loss of potency often occur during Protein A chromatography due to the harsh acidic conditions required for antibody elution. This study presents a pH ...

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

Complete proteins, which include meat and dairy products, make that a little easier because you'll get all nine essential ...